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Abstract 
Aims: Predicting incident diabetes could inform treatment strategies for diabetes prevention, but 
the incremental benefit of recalculating risk using updated risk factors is unknown. We used 
baseline and 1-year data from the Nateglinide and Valsartan in Impaired Glucose Tolerance 
Outcomes Research (NAVIGATOR) Trial to compare diabetes risk prediction using historical or 
updated clinical information. 
Methods: Among non-diabetic participants reaching 1 year of follow-up in NAVIGATOR, we 
compared the performance of the published baseline diabetes risk model with a “landmark” 
model incorporating risk factors updated at the 1-year time point. The C-statistic was used to 
compare model discrimination and reclassification analyses to demonstrate the relative accuracy 
of diabetes prediction.  
Results: A total of 7527 participants remained non-diabetic at 1 year, and 2375 developed 
diabetes during a median of 4 years of follow-up. The C-statistic for the landmark model was 
higher (0.73 [95% CI 0.72–0.74]) than for the baseline model (0.67 [95% CI 0.66–0.68]). The 
landmark model improved classification to modest (<20%), moderate (20%–40%), and high 
(>40%) 4-year risk, with a net reclassification index of 0.14 (95% CI 0.10–0.16) and an 
integrated discrimination index of 0.01 (95% CI 0.003–0.013). 
Conclusions: Using historical clinical values to calculate diabetes risk reduces the accuracy of 
prediction. Diabetes risk calculations should be routinely updated to inform discussions about 
diabetes prevention at both the patient and population health levels. 
 
Keywords: diabetes risk prediction, impaired glucose tolerance 
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1. Introduction 
The use of diabetes risk prediction tools is advocated to identify high-risk individuals who 
should be screened more frequently for the development of diabetes or who may benefit from 
intensive diabetes prevention strategies [1-3]. The available risk calculators and outcome 
prediction tables use a given set of risk factors to model the likelihood of developing diabetes 
over a defined follow-up period. There is little consensus as to which risk prediction tool is most 
appropriate, and most have limited applicability due to the small size or limited ethnic variability 
in the populations from which they were derived. 
With the rising global incidence of diabetes, there is interest in improving the 
performance of risk prediction tools, at both an individual and a population health level. Some 
have sought to improve prediction by adding additional genetic [4], laboratory [5, 6], or clinical 
[7] parameters to the traditional sociodemographic risk factors of ethnicity, family history of 
diabetes, personal history of gestational diabetes, and physical inactivity. Comparatively little is 
known about the impact of change in common risk factors over time on risk prediction [8]. Using 
data from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research 
(NAVIGATOR) study (ClinicalTrials.gov NCT00097786), we investigated the incremental 
benefit to diabetes risk prediction of updating risk factors after 1 year of follow up [9-11].   
 
2. Materials and Methods 
The NAVIGATOR study design and results have been previously published [9-11]. Briefly, 
9306 participants with impaired glucose tolerance (IGT) and cardiovascular disease or 
cardiovascular risk factors were enrolled from 40 countries between January 2002 through 
January 2004. Subjects were randomized to nateglinide and/or valsartan in a balanced 2 × 2 
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factorial design; all participants received a study-specific lifestyle modification program. After 
randomization, fasting plasma glucose was measured every 6 months for 3 years and annually 
thereafter. Oral glucose tolerance tests (OGTTs) were performed annually. HbA1c was measured 
only at baseline. Progression to diabetes occurred if the participant had a fasting plasma glucose 
level ≥126 mg/dL (≥7.0 mmol/L) or ≥200 mg/dL (≥11.1 mmol/L) 2 hours after a glucose 
challenge, confirmed by OGTT within the following 12 weeks. The date of diabetes onset was 
the date of the first elevated glucose value. Among 183 patients, diabetes was diagnosed outside 
of the study but confirmed by an independent adjudication committee. Subjects were followed 
for a median of 5 years for the incidence of diabetes.  
A model using baseline characteristics to predict 5-year incident diabetes has been 
previously published [12]. Here, we compared the performance of the baseline model to a Cox 
proportional hazards regression model whose inputs included information obtained after 1 year 
of trial follow-up (referred to as updated values). This model (hereafter referred to as the 
landmark model) predicts 4-year incident diabetes among patients who survived to 1 year 
without developing diabetes. The selection of predictors followed that used for creation of the 
baseline model: 10 baseline variables were forced into the model, selected according to clinical 
judgment rather than statistical significance (age, sex, race, body mass index [BMI], systolic 
blood pressure, family history of diabetes, history of cardiovascular disease, fasting glucose, 2-
hour glucose, and HbA1c). Subsequently, candidate variables were added by forward selection 
with a P-value of <0.05. Where updated risk factor measurements (collected at 1 year) were 
available, they replaced the baseline variables. Updated measurements were available for history 
of cardiovascular events, BMI, systolic blood pressure, fasting and 2-hr glucose levels, and 
platelet count. Updated risk factor measurements were not available for time constant covariates 
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(e.g., race, region), HbA1c, LDL, or HDL. In addition, wherever both baseline and 1-year risk 
factor measurements were available, the change from baseline to 1 year (calculated as the 
baseline value minus the 1-year value) was a candidate variable.  
Because the baseline model was developed in a different population, possibly hindering 
its performance relative to the landmark model, we also refitted the baseline model covariates to 
the 1-year follow-up population, resulting in a model that used only baseline data but was 
calibrated to the population of interest. For a sensitivity analysis, we repeated the comparisons 
using this alternative baseline model. The competing risk of death was handled by modeling the 
cause-specific hazard of diabetes progression, with censoring at the time of death. This 
methodology mirrors that used for analyzing the diabetes endpoint for the primary trial.    
As previously reported, less than 3% of data were missing for baseline covariates except 
HbA1c, which had 15% missing [12]. For the 1-year updated values, the highest missing rate was 
10% for platelet count. The missing data were handled by multiple imputation, and the final 
model results, standard errors, C-indices, and predicted probabilities reflect the combined results 
from five imputed data sets. Baseline and landmark models were compared according to the C-
index, which is a measure of a model’s ability to discriminate risk ranging from 0.5 (poor) to 1 
(perfect) [13]. Model calibration was assessed graphically with observed event rates plotted 
against predicted event rates over deciles of predicted risk.  
As a second comparison of model performance, risk classification tables were created to 
compare the baseline and landmark models for predicting transition to diabetes. Participants 
were classified by risk of progression to diabetes: modest risk (0–5%/year or 0–20% 4-year risk), 
moderate risk (>5–10%/year or >20–40% 4-year risk), or high risk (>10%/year or >40% 4-year 
risk). This clinically motivated classification paradigm is identical to that previously described 
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and is based on the annual diabetes risk seen in the placebo groups of other diabetes prevention 
studies [9]. Risk reclassification tables show the differences in classification, when compared to 
observed Kaplan-Meier event rates. Net reclassification index (NRI) and the integrated 
discrimination index (IDI) are also reported, using methods for censored data [14, 15].  
SAS statistical software (Version 9.2, SAS Institute, Cary, NC, USA) was used for all 
statistical analyses. 
 
3. Results 
The population for this analysis included 7527 participants who did not die, convert to diabetes, 
or drop out of the study before the 1-year landmark time point (Table 1). Within this population, 
2375 converted to diabetes within the next 4 years of follow-up. The results of prediction in the 
baseline and landmark population are shown in Table 2 (see Supplemental Material for 
predictive equation). The C-index of 0.73 (95% CI 0.72–0.74) indicates improved discrimination 
of 4-year incident diabetes in the landmark model compared with the baseline model (C-index 
0.67 [95% CI 0.66–0.68]), although both had good calibration (not shown). All of the updated 
values made significant contributions to the model, with the exception of updated history of 
cardiovascular disease and platelet count. Change variables for fasting and 2-hour glucose and 
BMI made significant contributions to the model, but change in systolic blood pressure, the 
history of cardiovascular disease, platelet count, and hemoglobin did not.  
Table 3 compares the predicted 4-year incident diabetes risk for each model with the 
observed risk from Kaplan-Meier probability estimates. The landmark model consistently 
predicts observed event rates more accurately than the baseline model, with the exception of 77 
(1.0%) participants predicted to be of modest risk when the actual risk was moderate (predicted 
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risk <20%, observed risk 24%). The corresponding NRI was 0.14 (95% CI 0.10–0.16), and the 
IDI was 0.01 (95% CI 0.003–0.013). In the sensitivity analysis, where baseline data were fit to 
the landmark population, we saw very little difference in performance (C-index of 0.67 [95% CI 
0.66–0.69], NRI 0.20 [95% CI 0.17–0.22], and IDI 0.06 [95% CI 0.05–0.06]). 
 
4. Discussion 
We have demonstrated that updating risk factor values for a few key variables improves risk 
prediction for incident diabetes. These key variables are typically available in routine care of at 
risk patients: BMI, systolic blood pressure, measures of glucose, and hemoglobin. The change 
over 1-year follow-up in fasting and 2-hour blood glucose and BMI is also important. Based on 
hazard ratios and chi-square values in Table 2, the absolute level of blood glucose (fasting or 2-
hour values) is a stronger predictor of progression to diabetes than changes in glucose, but the 
change in BMI has a greater impact on risk prediction than the absolute level. This may imply 
that greater emphasis should be placed on large weight changes rather than absolute weight 
values when considering diabetes risk. The interim occurrence of cardiovascular events or 
change in systolic blood pressure does not impact prediction for diabetes.   
Baseline variables shown here to be significantly associated with diabetes prediction are 
largely consistent with those in other predictive models. Increasing age and HDL-cholesterol 
levels predict decreased risk of incident diabetes, while family history of type 2 diabetes and 
increasing HbA1c are associated with increased diabetes risk. Of interest is our finding that 
higher baseline LDL-cholesterol levels are associated with a reduced risk for 4-year incident 
diabetes as other diabetes risk models have not identified LDL-cholesterol as an independent 
predictor of diabetes [3, 6, 16].  Associations between LDL-cholesterol subfractions, e.g., 
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lipoprotein (a), and risk for diabetes have been inconsistent [17, 18]. However, lipid lowering 
with statin medications has been associated with increased diabetes risk in both epidemiological 
studies [19-22] and meta-analyses of prospective clinical trials [23-25]. Whether these findings 
and ours indicate a possible direct link with LDL-cholesterol or whether there is confounding as 
a result of statin therapy deserves further consideration.   
Examination of the chi-square values demonstrates that glucose measures are the 
strongest predictors of progression, in both baseline and landmark models.  The next largest chi-
square values are seen for the change in fasting and 2-hour glucose. Closer examination appears 
to show a counterintuitive result: an increased hazard if glucose values decrease from baseline to 
1 year. To understand this apparent paradox, it is important to remember that when change 
variables are added to the model, the effects are interpreted holding all other covariates (e.g., the 
absolute glucose value) constant (Figure 1). Among two people with equivalent 1-year fasting 
glucose, the individual whose glucose decreases over 1 year of follow-up had a higher glucose, 
on average, than a person who increases to the same point. Therefore, a person with higher 
average glucose is more likely to progress to diabetes than a person with lower average glucose. 
Our results suggest that the change in glucose values is important, in that it captures information 
about previous levels.  
The reclassification table demonstrates the incremental benefit of updating risk 
calculations. In every case of discrepancy between the models, the observed event rates were 
consistent with the landmark model classification but not the baseline model classification. A 
striking example is the 481 patients classified as moderate risk (20-40%) by the baseline model 
but high risk (>40%) by the landmark model. The observed 4-year event rate in these patients 
was 59%. If applied across a population health setting, this degree of misclassification could 
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result in highly inaccurate estimates of the cost and effort required for diabetes prevention 
interventions to be effective. 
There are important limitations to these findings. First, the NAVIGATOR population was 
constrained at entry by baseline glucose values. To be eligible, participants were required to have 
either IGT or fasting plasma glucose of at least 95 mg/dL (5.3 mmol/L) but <126 mg/dL (7.0 
mmol/L). Therefore, our models are only generalizable to populations first identified to have 
elevated fasting glucose or IGT and then followed forward for 1 year. This is a particularly 
important limitation given the strength of the fasting and 2-hour glucose levels as predictors in 
both the baseline and landmark models. By definition, there is a wider distribution of glucose 
values in the population at the 1-year time point, potentially contributing to the improved 
discrimination seen in the landmark model. Another limitation is that, due to the study design, 
updated 1-year values were not available for all variables (e.g., LDL, HDL), but it seems 
unlikely that the impact of these variables would outweigh that seen for the glucose variables. 
Lifestyle modification [26, 27] and metformin treatment [26] have proven efficacy for 
diabetes prevention. However, patients often find it difficult to implement and maintain the 
changes in diet and exercise required to reap the benefits. Furthermore, although recommended 
by the American Diabetes Association and other international guidelines [28], metformin is not 
formally approved for diabetes prevention, causing some payers not to reimburse its use for 
patients with IGT. These barriers, combined with poor uptake of screening for diabetes in many 
health care systems, decrease the ability to cope with the growing incidence of diabetes 
worldwide. Diabetes prediction tools could help to better target individuals at highest risk of 
conversion to diabetes for receipt of diabetes prevention interventions. However, our findings 
demonstrate that using historical data to inform diabetes risk calculations may underestimate the 
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true magnitude of the problem. In a cohort with IGT followed in clinical practice, diabetes risk 
calculations should be routinely updated to inform discussions about diabetes prevention at both 
the patient and population health levels. 
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Table 1 – Baseline characteristics of the overall NAVIGATOR population and those included in 
the landmark analysis. Categorical variables are presented as n/N, and proportion and continuous 
variables are presented as N, median (25th - 75th percentile).   
 
Characteristic 
Baseline Value (All 
Navigator patients) 
(N=9306) 
Baseline Value 
(Patients in 1-year 
model) 
(N=7527) 
Year 1 Value 
(Patients in 1-year 
model) 
(N=7527) 
Age  9306, 63.0 (58.0-69.0) 7527, 63.0 (58.0-69.0)  
Female 4711/9306 (50.6%) 3815/7527 (50.7%)  
Racea    
White 7734/9306 (83.1%) 6212/7527 (82.5%)  
Black 236/9306 (2.5%) 175/7527 (2.3%)  
Oriental 613/9306 (6.6%) 537/7527 (7.1%)  
Other 723/9306 (7.8%) 603/7527 (8.0%)  
Region    
Asia 552/9306 (5.9%) 487/7527 (6.5%)  
Europe 4909/9306 (52.8%) 3958/7527 (52.6%)  
Latin America 1406/9306 (15.1%) 1176/7527 (15.6%)  
North America 2146/9306 (23.1%) 1658/7527 (22.0%)  
Other 293/9306 (3.1%) 248/7527 (3.3%)  
Family History of Diabetes 3547/9306 (38.1%) 2845/7527 (37.8%)  
Prior Cardiovascular Diseaseb 7838/9306 (84.2%) 6346/7527 (84.3%) 222/7527 (2.9%) 
    
BMI kg/m2  9303, 29.7 (26.8-33.3) 7524, 29.5 (26.7-33.1) 7408, 29.3 (26.4-33.0) 
Systolic BP, mmHg  9282, 140.0 (128.0-150.0) 7510, 140.0 (128.0-150.0) 7419, 133.5 (122.5-144.0) 
Fasting Glucose, mmol/L  9300, 6.1 (5.7-6.4) 7522, 6.1 (5.7-6.4) 7358, 5.9 (5.5-6.3) 
Two Hour Glucose, mmol/L  9301, 9.0 (8.4-9.9) 7523, 9.0 (8.3-9.9) 6953, 7.9 (6.6-9.3) 
HbA1c, %  7905, 5.8 (5.6-6.1) 6481, 5.8 (5.5-6.1) 1146, 5.8 (5.5-6.1) 
LDL, mmol/L  8890, 3.2 (2.6-3.9) 7200, 3.2 (2.6-3.9) 206, 3.1 (2.5-3.6) 
HDL, mmol/L  9146, 1.2 (1.0-1.5) 7401, 1.2 (1.0-1.5) 215, 1.2 (1.0-1.5) 
Platelet, 10-9/L  9050, 251.0 (212.0-294.0) 7323, 251.0 (212.0-295.0) 6760, 246.0 (207.0-290.0) 
Hemoglobin, g/L  9137, 147.0 (138.0-155.0) 7397, 146.0 (138.0-155.0) 6825, 144.0 (136.0-153.0) 
    
Variables Not in Model     
Medical History    
   Family History of Premature Coronary Heart 
Disease 
1544/9306 (16.6%) 1229/7527 (16.3%)  
   Renal Dysfunction 90/9306 (1.0%) 66/7527 (0.9%)  
   Atrial Fibrillation/Flutter 356/9306 (3.8%) 272/7527 (3.6%)  
   Pulmonary Embolism or Deep Vein Thrombosis 129/9306 (1.4%) 99/7527 (1.3%)  
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Characteristic 
Baseline Value (All 
Navigator patients) 
(N=9306) 
Baseline Value 
(Patients in 1-year 
model) 
(N=7527) 
Year 1 Value 
(Patients in 1-year 
model) 
(N=7527) 
   COPD, Emphysema, or Chronic Bronchitis 451/9306 (4.8%) 333/7527 (4.4%)  
Current Smoker 1025/9306 (11.0%) 792/7527 (10.5%)  
Height (cm)   9303, 165.0, 158.0-173.0 7524, 165.0, 158.0-173.0  
Weight (kg)  9306, 82.0, 71.5-93.5 7527, 81.8, 71.0-92.8  
Waist Circumference (cm)  9297, 100.0, 92.0-109.0 7522, 100.0, 92.0-108.0  
Diastolic BP, mmHg  9282, 82.0, 76.0-90.0 7510, 82.0, 76.0-90.0  
Pulse, bpm  9267, 70.0, 63.0-77.0 7499, 70.0, 63.0-77.0  
ECG Interpretation (N)    
Normal 4400/9061 (48.6%) 3610/7349 (49.1%)  
Clinically Insignificant Abnormality 3271/9061 (36.1%) 2634/7349 (35.8%)  
Clinically Significant Abnormality 1390/9061 (15.3%) 1105/7349 (15.0%)  
Total Cholesterol, mmol/L 9266, 5.36, 4.67-6.10 7496, 5.36, 4.68-6.10  
Triglycerides, mmol/L  9261, 1.69, 1.22-2.36 7492, 1.69, 1.22-2.35  
eGFR, mL/min per 1.73 m2  9267, 79.7, 68.6-91.1 7497, 79.9, 68.8-91.3  
Log of Albumin/Creatinine Ratio, mg/mmol  9062, -0.22, -0.67-0.49 7344, -0.22, -0.69-0.47  
a Regions are defined as Asia: China (mainland), Hong Kong, Malaysia, Singapore, Taiwan; Europe: Austria, 
Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, 
Poland, Russia, Slovakia, Sweden, Switzerland, Spain, Turkey, UK; Latin America: Argentina, Brazil, Chile, 
Colombia, Ecuador, Guatemala, Mexico, Peru, Uruguay; North America: Canada, USA (incl. Puerto Rico); Other: 
Australia, New Zealand, South Africa.  
b Prior cardiovascular disease: history of myocardial infarction, unstable angina, percutaneous coronary intervention, 
coronary artery bypass grafting, stroke, or congestive heart failure. 
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Table 2 – Landmark proportional hazards model for 4-year incident diabetes.  
Main NAVIGATOR Model Variable HR (95% CI) Chi-Square P Value 
Age (per 10 years) a 0.89 (0.83–0.94) 13.53 0.0002 
Female sex a 1.11 (1.00–1.23) 3.83 0.051 
Region (vs. North America) b 
   Asia 0.94 (0.77–1.13) 0.48 0.49 
Europe 0.87 (0.77–0.97) 6.48 0.011 
Latin America 0.96 (0.83–1.11) 0.35 0.56 
Other 0.87 (0.68–1.11) 1.22 0.27 
Race (vs. White) a 
   Other 0.95 (0.80–1.13) 0.30 0.59 
Black 0.90 (0.68–1.19) 0.57 0.45 
Family history of type 2 diabetes mellitus a 1.13 (1.04–1.23) 7.66 0.0056 
LDL (mmol/L) 0.93 (0.89–0.98) 8.57 0.0034 
HDL (mmol/L) 0.76 (0.66–0.87) 15.51 <0.0001 
HbA1c (%)a 1.71 (1.54–1.89) 101.77 <0.0001 
Values at 1 year 
   Fasting glucose (mmol/L) a 1.68 (1.59–1.79) 298.54 <0.0001 
2-hour glucose (mmol/L) a 1.43 (1.37–1.49) 250.88 <0.0001 
BMI (kg/m2) a 1.01 (1.00–1.02) 5.24 0.022 
Prior cardiovascular disease, baseline/1 year a,c 1.07 (0.98–1.17) 2.09 0.15 
Systolic BP (per 10 mm Hg) a 1.03 (1.01–1.06) 5.31 0.021 
Hemoglobin (per 10 g/L) 1.08 (1.04–1.12) 16.06 <0.0001 
Change from baseline to 1 yeard 
   Fasting glucose (mmol/L) 1.35 (1.23–1.49) 38.50 <0.0001 
2-hour glucose (mmol/L) 1.22 (1.17–1.28) 78.91 <0.0001 
BMI (kg/m2) 0.88 (0.85–0.91) 53.11 <0.0001 
For each dataset: N=7527, Event=2375, C-index=0.73.  
a Forced into model.  
b Regions are defined as Asia: China (mainland), Hong Kong, Malaysia, Singapore, Taiwan; Europe: Austria, 
Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Netherlands, Norway, 
Poland, Russia, Slovakia, Sweden, Switzerland, Spain, Turkey, UK; Latin America: Argentina, Brazil, Chile, 
Colombia, Ecuador, Guatemala, Mexico, Peru, Uruguay; North America: Canada, USA (incl. Puerto Rico); Other: 
Australia, New Zealand, South Africa.  
c Prior cardiovascular disease: history of cardiovascular disease includes myocardial infarction, unstable angina, 
percutaneous coronary intervention, coronary artery bypass grafting, stroke, or congestive heart failure. 
d Change is calculated as the baseline minus 1-year value. Therefore, an increase in the change value reflects 
improvement in the clinical situation.   
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Table 3 – Reclassification table for baseline versus landmark diabetes prediction models.   
Baseline Model Landmark Model 
 
Modest risk (<20%) Moderate risk (20–40%) High risk (>40%) Total 
Modest  risk (<20%) 
2071a 648 b 58 b 
2777 
(0.09) (0.25) (0.60) 
Moderate risk (20–40%) 
948 b 1795 a 481 b 
3224 
(0.15) (0.29) (0.59) 
High risk (>40%) 
77 b 648 b 801 a 
1526 
(0.24) (0.37) (0.62) 
Total 3096 3091 1340 7527 
Kaplan-Meier (KM) estimates of the 4-year risk of diabetes progression. In each cell, the number of individuals in 
each risk category is shown, followed by the observed 4-year incident diabetes risk according to KM probability 
estimates. C index from baseline model 0.67, from landmark model 0.73.  
a KM rates are consistent with the landmark and baseline model classifications. 
b KM rates are consistent with the landmark model classification, but not the baseline. 
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Figure 1 – Clinical example illustrating interpretation of change values for fasting glucose.  
Change values in the model are interpreted holding all other variables constant. Therefore, 
among two individuals with an equivalent 1-year fasting plasma glucose (FPG), Individual A, 
whose fasting glucose decreases over time, had a higher baseline glucose value than an 
individual whose glucose increases to the same point. Therefore, Individual A carries a higher 
overall risk for developing diabetes. The change value captures information about the absolute 
change in glucose level and some information about the baseline value as well.   
 
 
